Recent developments in the treatment of peripheral T-cell lymphoma

被引：0
作者：
Hopfinger G. [1 ]
Weit N. [2 ]
Herling M. [2 ]
机构：
[1] 3rd Department of Medicine, Hanusch Krankenhaus, 1140 Vienna
[2] 1st Department of Medicine, Cologne
来源：
memo - Magazine of European Medical Oncology | 2010年 / 3卷 / 2期
关键词：
Peripheral T-cell lymphoma; Pralatrexate; Romidepsin; Vorinostat;
D O I：
10.1007/s12254-010-0191-x
中图分类号：
学科分类号：
摘要：
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of lymphatic neoplasms, which originate from mature (post-thymic) T-cells. Although comprising less than 15% of all non-Hodgkin lymphomas (NHL) in adults in Western countries, T-cell lymphomas still pose a considerable clinical challenge. To date, no standard therapy is available for the treatment of these T-cell malignancies. Treatment options that brought about substantial clinical progress in B-cell lymphomas perform only very poorly when used for T-cell lymphomas. With standard chemotherapy such as CHOP approximately 30% of T-cell lymphomas show a primary refractory course and only 35% of patients survive after 3-5 years. Therefore, novel treatment approaches need to be designed and validated in clinical trials. Here we discuss recent data including those presented at the last annual meeting of the American Society of Haematology (ASH 2009). Currently under investigation are new treatment modalities such as immune odulatory drugs, antifolates or histone deacetylase inhibitors. In addition, we present the ongoing trials that incorporate hese new modalities. © Springer-Verlag 2010.
引用
收藏
页码：73 / 76
页数：3
相关论文
共 18 条
  • [11] Pinter-Brown L., Horwitz S., Pro B., Et al., Safety and management of pralatrexate treatment in relapsed or refractory peripheral T-cell lymphoma (PTCL), ASH Annual Meeting Abstr., 111, (2009)
  • [12] Buglio D., Georgakis G.V., Hanabuchi S., Et al., Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines, Blood, 112, pp. 1424-1433, (2008)
  • [13] Duvic M., Kim Y.H., Kuzel T.M., Et al., The Systemic effects of vorinostat in patients (Pts) with cutaneous T-cell lymphoma (CTCL): Post-hoc analyses in Pts with high blood tumor burden, ASH Annual Meeting Abstr., 111, (2009)
  • [14] Piekarz R., Wright J., Frye R., Et al., Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL), ASH Annual Meeting Abstr., 111, (2009)
  • [15] Pohlman B., Advani R., Duvic M., Et al., Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma, ASH Annual Meeting Abstr., 111, (2009)
  • [16] Dimopoulos M.A., Garcia-Sanz R., Gavriatopoulou M., Et al., Primary therapy of waldenstrom's macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone and rituximab (BDR): A phase II study of the European myeloma network, ASH Annual Meeting Abstr., 111, (2009)
  • [17] Fowler N., Kahl B.S., Rosen P., Et al., Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: Encouraging activity in the phase 2 VERTICAL study, ASH Annual Meeting Abstr., 111, (2009)
  • [18] Ozpuyan F., Meyer P., Ni H., Et al., Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL), Leuk Lymphoma, 48, pp. 2247-2250, (2007)
12